New Classifications of Five Distinct “Sleep” Profi... ...
Science in the Age of AI | AI for Science Forum...
Ask the Heart Doctor | Heart Valve Disease and Sur...
High-speed imaging tracks live brain cell activity...
NAD⁺ restores memory in Alzheimer's disease models...
Mark Cuban: A Master Disrupter for American Health...
Teen girls facing the most adversity showed the biggest gain...
September 15,2026
Specialized imaging reveals hormone-driven brain changes...
September 14,2026
Submillimeter MRI reveals brain hubs that guide risky decisi...
September 12,2026
Risk of herpes zoster among breast cancer survivors in Japan...
September 11,2026
Three proteins help organs tailor shared circadian clock to ...
September 10,2026
Should you worry about melatonin and heart failure? The evid...
December 02,2025
Category
Traditional Medicine
Q & A
Wellness
Drug Discovery
Technology & AI
Clinical Pearl Series
Breakthroughs
Immunology & Rheumatology
Reproduction
Hepatobiliary&Pancreas Surgery
Most Read
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and Sex

Blood Pressure Chart With Readings By Age and SexAverage Ranges Show Normal Pressure On the ArteriesBySheryl Huggins SalomonUpdated on April 21, 2023Medically reviewed byJeffre
Cardiovascular Diseases April 07,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals Advances Hair Loss Treatment with Phase 2 Study and $14M Funding

Pelage Pharmaceuticals has commenced dosing the first patients in its Phase 2a clinical trial for PP405, a novel topical treatment designed to reactivate dormant hair follicle stem cells.
Dermatology August 14,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs Mean

Blood Types: What Letters, Positive, and Negative Signs MeanWhat to Know About Your Blood TypeByNancy LeBrunPublished on September 15, 2023Medically reviewed byAnju Goel, MDYou
Oncology March 17,2024
Today's News
GOSH BRC Showcase 2025 - Genomic medicine...
Can a twice-a-year shot help end the HIV...
Announcement of the 2025 Nobel Prize in ...
Reprogramming Stem Cells Could Cure Type...
Why MDMA did NOT get FDA approval...
More News
To rev-up CAR T-cell therapy, inhibit the SUSD2 membrane protein, study suggests

To rev-up CAR T-cell therapy, inhibit the SUSD2 membrane protein, study suggests

byOhio State University Medical CenterCredit: Pixabay/CC0 Public DomainInhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T-cell and
Oncology January 22,2024
To rev-up CAR T-cell therapy, inhibit the SUSD2 membrane protein, study suggests

To rev-up CAR T-cell therapy, inhibit the SUSD2 membrane protein, study suggests

byOhio State University Medical CenterCredit: Pixabay/CC0 Public DomainInhibiting a particular protein in cancer-killing immune cells might improve the long-term effectiveness of CAR T-cell and
Oncology January 22,2024
Study links poverty to increased acute lymphoblastic leukemia relapse

Study links poverty to increased acute lymphoblastic leukemia relapse

by Brianna Hoge,University of Alabama at BirminghamCredit: Pixabay/CC0 Public DomainA new study from the University of Alabama at Birmingham's Marnix E. Heersink School of Medicine suggests
Oncology January 22,2024
Study links poverty to increased acute lymphoblastic leukemia relapse

Study links poverty to increased acute lymphoblastic leukemia relapse

by Brianna Hoge,University of Alabama at BirminghamCredit: Pixabay/CC0 Public DomainA new study from the University of Alabama at Birmingham's Marnix E. Heersink School of Medicine suggests
Oncology January 22,2024
Study sends strong signal not to sequence immune checkpoint inhibitors in advanced kidney cancer

Study sends strong signal not to sequence immune checkpoint inhibitors in advanced kidney cancer

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainPatients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment. The CONTACT-0
Oncology January 22,2024
Study sends strong signal not to sequence immune checkpoint inhibitors in advanced kidney cancer

Study sends strong signal not to sequence immune checkpoint inhibitors in advanced kidney cancer

byDana-Farber Cancer InstituteCredit: Pixabay/CC0 Public DomainPatients with advanced kidney cancer are routinely given immune checkpoint inhibitors (ICIs) as first-line treatment. The CONTACT-0
Oncology January 22,2024
Blood cancer manipulates immune cells in order to survive, study shows

Blood cancer manipulates immune cells in order to survive, study shows

byWellcome Trust Sanger InstituteCredit: Pixabay/CC0 Public DomainThe most comprehensive study to date of the blood cancer, Hodgkin lymphoma, has provided fascinating insights into what tumor ce
Oncology January 22,2024
Blood cancer manipulates immune cells in order to survive, study shows

Blood cancer manipulates immune cells in order to survive, study shows

byWellcome Trust Sanger InstituteCredit: Pixabay/CC0 Public DomainThe most comprehensive study to date of the blood cancer, Hodgkin lymphoma, has provided fascinating insights into what tumor ce
Oncology January 22,2024
Study illuminates precancerous 'clonal outgrowth' in blood cells

Study illuminates precancerous 'clonal outgrowth' in blood cells

byWeill Cornell Medical CollegeCredit: CC0 Public DomainA common, spontaneous mutation in blood stem cells, which has been linked to higher risks of blood cancer and cardiovascular disease, may
Oncology January 22,2024
Study illuminates precancerous 'clonal outgrowth' in blood cells

Study illuminates precancerous 'clonal outgrowth' in blood cells

byWeill Cornell Medical CollegeCredit: CC0 Public DomainA common, spontaneous mutation in blood stem cells, which has been linked to higher risks of blood cancer and cardiovascular disease, may
Oncology January 22,2024
Study examines hesitation toward potential changes to bowel cancer surveillance

Study examines hesitation toward potential changes to bowel cancer surveillance

byFlinders UniversityCredit: Pixabay/CC0 Public DomainAs doctors and researchers discuss whether to push recommended bowel cancer colonoscopy surveillance intervals out beyond five years, new re
Oncology January 22,2024
Study examines hesitation toward potential changes to bowel cancer surveillance

Study examines hesitation toward potential changes to bowel cancer surveillance

byFlinders UniversityCredit: Pixabay/CC0 Public DomainAs doctors and researchers discuss whether to push recommended bowel cancer colonoscopy surveillance intervals out beyond five years, new re
Oncology January 22,2024
Study: Conventional radiotherapy should remain standard of care for localized vertebral metastases of the spine

Study: Conventional radiotherapy should remain standard of care for localized vertebral metastases of the spine

by NRG OncologyCredit: Pixabay/CC0 Public DomainResults from the NRG Oncology RTOG 0631 clinical trial comparing stereotactic vs. conventional radiotherapy for localized vertebral metastases of the sp
Oncology January 22,2024
Study: Conventional radiotherapy should remain standard of care for localized vertebral metastases of the spine

Study: Conventional radiotherapy should remain standard of care for localized vertebral metastases of the spine

by NRG OncologyCredit: Pixabay/CC0 Public DomainResults from the NRG Oncology RTOG 0631 clinical trial comparing stereotactic vs. conventional radiotherapy for localized vertebral metastases of the sp
Oncology January 22,2024
Rethinking how cancer cells evade targeted therapy

Rethinking how cancer cells evade targeted therapy

byUniversity of California, San FranciscoA single-cell RNA atlas of human glioblastoma through recurrence.a, An overview of genomics studies on paired longitudinal GBM specimens.b, A
Oncology January 22,2024
Rethinking how cancer cells evade targeted therapy

Rethinking how cancer cells evade targeted therapy

byUniversity of California, San FranciscoA single-cell RNA atlas of human glioblastoma through recurrence.a, An overview of genomics studies on paired longitudinal GBM specimens.b, A
Oncology January 22,2024
Prognosis of multiple myeloma has improved since 2000

Prognosis of multiple myeloma has improved since 2000

by Elana GotkineFor patients with multiple myeloma (MM), there has been an improvement in prognosis since 2000, but mortality still remains elevated, according to a study published online April 6 in&n
Oncology January 22,2024
Prognosis of multiple myeloma has improved since 2000

Prognosis of multiple myeloma has improved since 2000

by Elana GotkineFor patients with multiple myeloma (MM), there has been an improvement in prognosis since 2000, but mortality still remains elevated, according to a study published online April 6 in&n
Oncology January 22,2024
Minimal residual disease negativity predicts time to next treatment in multiple myeloma

Minimal residual disease negativity predicts time to next treatment in multiple myeloma

by Elana GotkineFor patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTN
Oncology January 22,2024
Minimal residual disease negativity predicts time to next treatment in multiple myeloma

Minimal residual disease negativity predicts time to next treatment in multiple myeloma

by Elana GotkineFor patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTN
Oncology January 22,2024
More News
Week’s Top
Podcasts
... Health spending has been rising across rich countries with different systems ... ... GOSH BRC Showcase 2025 - Genomic medicine ... ... At what age do people experience depression for the first time? Depression can affect people over long periods of their lives. Some people experience this condition continuously, while for others, it occu...
FIND US ON
ABOUT
Who We Are
Contact Us
Editorial Team
Sitemap
Policy
Privacy Policy
Advertising Policy
Editorial Policy
Corrections Policy
Medical Disclaimer
Alliance
wmo.com
sleep.net
pharm.net
doctors.net
worldsleep.com